JAK/TYK2
2 years ago
ORAL surveillance the big talking factor over the last year.
NNH of 16(!) for CV event (over 5 yrs) in those with history of atherosclerotic CV disease.
@RheumNow #ACR22 #yearinreview #ACRBest
2 years ago
Great start to year in review.
Beginning with JAKinibs in the much talked about ORAL Surveillance study.
Good Review of the mechanisms of action for JAKinibs
@RheumNow #ACR22 https://t.co/IF0t4uSefj
ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick…
The management of rheumatoid arthritis patients with a history of cancer continues to be an area of concern for rheumatologists. General recommendations are to treat patients with a history of solid…
There have been big advances in the treatment of axial spondyloarthritis (AxSpA) in the last decade.
Biologic drugs that target TNF and IL-17 have become mainstay treatments in AxSpA if the disease…
2 years ago
Abbvie launching another upadacitinib phase 3 trial w/essentially zero preliinary data
I personally love this strategy; I think Phase 2's are an expensive waste of time
Better to go big and answer the question?
COI: I participate in SELECT-GCA
#ACR22 @RheumNow #Vasculitis22 https://t.co/fSs3xt8baA
2 years ago
Does #COVID19 #vaccine work in #psoriaticarthritis? @RheumNow #ACR22 Abstract #0389
🤚 HR for infection and hospitalization similar between controls and PsA after 2nd vaccination
🤚#Enbrel (OR 2.39) and #JAKi (OR 9.90) higher risk of infection and hospitalization
After decades of having little else proven apart from glucocorticosteroids with which to treat polymyalgia rheumatica (PMR), evidence for steroid-sparing options has grown in recent years, and this…
The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do…
Poster Hall